

### WORLD HEALTH ORGANIZATION



XXXV Meeting

XLIII Meeting

Washington, D.C. September 1991

Provisional Agenda Item 2.10

CD35/7 (Eng.)
9 July 1991
ORIGINAL: ENGLISH

SELECTION OF ONE MEMBER GOVERNMENT FROM THE REGION OF THE AMERICAS TO THE MANAGEMENT ADVISORY COMMITTEE OF THE ACTION PROGRAM ON ESSENTIAL DRUGS

The objective of the WHO Program on Essential Drugs (APED), established in 1981, is to support Member States in ensuring the regular supply of essential drugs of acceptable quality and low cost, to help achieve the goal of health for all by the ye r 2000. The Program addresses the highly complex technological, social, political and economic issues involved in the development and implementation of national drug policies. In recognition of the sensitive and potentially controversial areas covered by the APED, the WHO Executive Board established a special Ad Hoc Committee on Drug Policies.

Until August 1988 the Program operated under the direct supervision of the Director-General. At that time it was incorporated into the newly established Division of Drug Policy and Management. The Division also includes other programs concerned with medicinal products: Pharmaceuticals, Biologicals, Traditional Medicine and Psychotropic and Narcotic Drugs. The integration of all drug-related programs is intended to provide for greater balance in the emphasis laid upon the various elements of WHO's Revised Strategy on Drugs.

The establishment of a Management Advisory Committee (MAC) similar to the one for the AIDS Program was considered needed for discussion of the managerial and policy issues encountered to ensure the continuity and coherence of the Essential Drugs Program, which has a wide range of activities funded primarily from sources outside the regular WHO budget. Terms of reference for the Committee were approved at the Third Meeting of Interested Parties, Geneva, 25-26 May 1989 (Annex I). The Committee has the formal responsibility for advising the Director-General on the policy, strategy, financing, management, monitoring and evaluation of the APED, while the Executive Board Committee on Drug Policies would report to the Executive Board on any matter on drug policy referred to it by the Board. The Chairman of the Executive Board is an ex officio member of the MAC.

The Regional Committee for the Americas selects two Member Governments entitled each to designate a person to serve on the MAC, according to the following scheme:

"With respect to regional representation the Committee agreed to adopt a system of 'staggered' change of membership to achieve a three-year cycle in which four out of the twelve regional members would be replaced each year. The Chairperson drew lots to determine which regions would be in which of the three categories. The result was as follows:

- Category 1: One member for 1 year and 1 member for 2 years: Africa, South-East Asia
- Category 2: One member for 1 year and 1 member for 3 years: Americas, Western Pacific
- Category 3: One member for 2 years and 1 member for 3 years: Europe, Eastern Mediterranean."

Attached for easy reference is a chart reflecting the above (Annex II).

The Governments of Bolivia and Ecuador were selected in 1990 by the XXIII Pan American Sanitary Conference for the terms from 1 January 1991 to 31 December 1991 and 1 January 1991 to 31 December 1993, respectively.

To provide the "staggered" change of membership, the Regional Committee is now requested to select one member to serve for three years, from 1 January 1992 to 31 December 1994.

Annexes

#### ACTION PROGRAMME ON ESSENTIAL DRUGS

#### Terms of reference of the Management Advisory Committee

The Management Advisory Committee (MAC) represents the interests and responsibilities of WHO's external partners collaborating with WHO in its Action Programme on Essential Drugs. It acts as an advisory body to the Director-General of WHO, making recommendations on matters related to the policy, strategy, finance, management, monitoring and evaluation of the WHO's Action Programme on Essential Drugs (APED).

#### **Functions**

- Review, analyse and guide the programme of activities and related budget of APED and make appropriate recommendations to the Director-General;
- Review the arrangements envisaged by the Director-General of WHO for financing and managing APED;
- Review proposed longer-term plans of action and their financial implications;
- Review of financial statements of APED;
- Review periodic reports evaluating the progress of APED towards the achievement of its objectives and submit its findings and recommendations to the Director-General;
- Recommend ways of improving, as appropriate, coordination between the activities of APED and of other relevant programmes and organizations; and
- Consider any other matters relating to APED referred to it by the Director-General of WHO, the Programme Manager of APED or any member of the Committee.

In carrying out its function, MAC shall be informed of all policy decisions and recommendations concerning APED or WHO's Revised Strategy on Drugs (RSD) made by the World Health Assembly and the Executive Board.

#### Composition

- The governments of those countries which contributed funding in support of APED's general budget in the previous fiscal year or which provided bilateral support to developing countries for the formulation or implementation of national drug policies in conformity with WHO's policies on essential drugs;

- Two Member States from each of WHO's six Regions selected by the respective Regional Committees for three-year terms from among those Member States with which APED is collaborating;
- The four major international organizations collaborating in the implementation of WHO's RSD, namely UNDP, UNICEF, UNIDO and the World Bank; and
- The Chairman or the Vice-Chairman of the Committee on Drug Policies of the Executive Board, or a member designated by the Chairman.

Representatives of governments and intergovernmental organizations not included on MAC as well as nongovernmental organizations involved in the RSD may, on request, be granted observer status.

The identity of those countries contributing funding in support of APED's general budget and those providing bilateral support in the above manner, and hence their eligibility for membership in MAC, shall be ascertained annually. Members selected from the six Regions of WHO may be reappointed. The four major international organizations shall be considered to have permanent seats for as long as they continue to participate in APED in support of WHO's RSD. The Chairperson of MAC should, in principle, be a government representative and shall be elected from and by members of MAC for a period of two years, but, while eligible for re-election, may not serve consecutive terms. The Chairperson shall preside over meetings of MAC and undertake whatever additional duties may be assigned by MAC, in agreement with the Director-General of WHO.

#### Operation

The MAC shall meet once a year. The Meeting shall concentrate on reviewing APED's programme for that year in light of the financial support that will have been pledged and the past, present, and future coordination of external support for APED's principal areas of activity (country support, development work and operational research). The meeting shall also review and guide the following year's programme and related budget. The MAC may also meet more often upon the proposal of either its Chairperson or the Director-General of WHO, and with the latter's agreement. The MAC shall decide its method of work, which may include the establishment of a number of functional subcommittees. All such subcommittees will have an advisory role to MAC. Each MAC meeting shall elect a rapporteur from among its members who shall assist in ensuring that the decisions reached by the meeting are adopted and recorded before its closure. The MAC should, wherever possible, adopt its conclusions by consensus. The Programme Manager of APED shall be the Secretary of MAC.

For these purposes, MAC shall be assisted in its endeavours by the provision by WHO of whatever secretariat and other support services may be considered necessary and reasonable.

### Review

At the second meeting of the MAC, its terms of reference as set out above will be reviewed in the light of members' experience.

# Management Advisory Committee (MAC) of the Action Programme on Essential Drugs

# REGIONAL REPRESENTATION 1991 - 1993

	1991	1992	1993	
AFR	Member 1			
	Member 2	Member 2		
AMR	Member 1			===
	Member 2	Member 2	Member 2	
EMR	Member 1	Member 1		===
	Member 2	Member 2	Member 2	
=======================================				===
EUR	Member 1	Member 1	**************************************	
	Member 2	Member 2	Member 2	
SEAR	Member 1			=== 
	Member 2	Member 2		
WPR	Member 1			===
	Member 2	Member 2	Member 2	